Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

June 26, 2024 updated by: Universitaire Ziekenhuizen KU Leuven
In this study PEAR1 polymorphisms effects will be analyze in blood platelets to determine how PEAR1 regulates platelet activation.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Several large-scale studies have confirmed the long held notion that platelet responses to different agonists are highly variable, within well defined populations of healthy donors. Single nucleotide polymorphisms in genes encoding platelet proteins can explain the wide range of responses to standard platelet agonists. Yet, numerous SNPs point towards proteins with previously unknown function in platelets, wich modulate the complex network of signaling events that regulate platelet function and further augment variability. PEAR1 is mainly expressed in platelets and endothelial cells. A few studies have linked SNPs in PEAR1 with decreased or increased platelet responses to various agonists. However, hitherto, no direct functional studies have been carried out to determine whether and how PEAR1 modulate intracellular signaling pathways relevant for platelet function.

Study Type

Observational

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgium, 3000
        • KUleuven/UZ Gasthuisberg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

healthy voluntary donors

Description

Inclusion Criteria:

  • healthy voluntary donors

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
peripheral blood
healthy voluntary donors
preparation of blood platelets

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marc Hoylaerts, KU Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Estimated)

May 1, 2012

Study Completion (Estimated)

May 1, 2012

Study Registration Dates

First Submitted

May 11, 2011

First Submitted That Met QC Criteria

May 11, 2011

First Posted (Estimated)

May 12, 2011

Study Record Updates

Last Update Posted (Actual)

June 28, 2024

Last Update Submitted That Met QC Criteria

June 26, 2024

Last Verified

May 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • B322201111373

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Platelet Function

Clinical Trials on blood test

Subscribe